Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting
Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…Abstract Number: 2606 • 2018 ACR/ARHP Annual Meeting
Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
Background/Purpose: Adalimumab (ADA) inhibited radiographic progression in patients (pts) with moderate to severe PsA in the ADEPT study and its open label extension (OLE). These…Abstract Number: 2607 • 2018 ACR/ARHP Annual Meeting
Early Achievement of ASDAS-Major Improvement in Patients with Ankylosing Spondylitis Treated with TNF-α Blockers Is Associated with a Prominent Longterm Improvement in Metrologic Indices
Background/Purpose: Limited spinal mobility is a cardinal sign of ankylosing spondylitis (AS) and shows a close relationship with functional disability which leads to high individual…Abstract Number: 2608 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, provided sustained improvement in the signs and symptoms of active psoriatic arthritis…Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…Abstract Number: 2610 • 2018 ACR/ARHP Annual Meeting
Certolizumab Pegol Serum Levels ≥20 Mg/L Are Associated with Treatment Response in Patients with Axial Spondyloarthritis
Background/Purpose: Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors.An association between certolizumab pegol (CP) serum levels and response has previously been…Abstract Number: 2611 • 2018 ACR/ARHP Annual Meeting
Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents
Background/Purpose: Lack of efficacy (LOE) to TNF inhibitor (TNFi) treatments is an important issue and can be seen in up to 40% of the patients…Abstract Number: 2612 • 2018 ACR/ARHP Annual Meeting
Utility of Infiltration with Steroids in Dactilitis. Is the Infiltration Guided By Ecography Better THAN Conventional?
Background/Purpose: Dactylitis, also called "sausage fingers", is considered one of the differential signs characteristic of Spondyloarthritis (SpA). The absence of knowledge of its pathophysiology make…Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…Abstract Number: 2614 • 2018 ACR/ARHP Annual Meeting
The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
Background/Purpose: The humoral response to vaccination may be affected by the use of immunosuppressive drugs. The effect of secukinumab on the humoral response of vaccines…Abstract Number: 2615 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio Registry
Background/Purpose: The aim of the study was to investigate the impact of smoking on disease activity, treatment adherence and treatment response in psoriatic arthritis (PsA)…Abstract Number: 2616 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio Registry
Background/Purpose: Although there is good evidence that smoking has a dose-dependent impact on structural damage progression in ankylosing spondylitis (AS) the evidence is poor for its…Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…
ACR Meeting Abstracts